Emerging therapies in allergic conjunctivitis and dry eye syndrome.
about
Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitisDrug utilization study in ophthalmology outpatients at a tertiary care teaching hospital.Phase II drugs under investigation for allergic conjunctivitis.Investigational drugs in dry eye disease.Mucosal immune tolerance at the ocular surface in health and disease.Dry Eye Management: Targeting the Ocular Surface Microenvironment.Clinical implications of mast cell involvement in allergic conjunctivitis.
P2860
Q26799723-41A238DB-E775-4763-AD0D-A73E20557E5FQ37449797-EF390D49-9B88-41DB-A80B-7D92C62BEFA0Q38234039-F95CC4B6-BA59-4101-92E9-0309F2EB4E7BQ38984001-6731F16A-9621-4735-863D-C2270A6B5E6CQ39097223-2E335933-F610-4118-9A82-4D20ABBF4CEFQ39404635-825DE443-BCC5-4913-90EC-AA9D62971749Q48361100-E28F4F11-3D12-478C-9BD1-79FF28A35F91
P2860
Emerging therapies in allergic conjunctivitis and dry eye syndrome.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging therapies in allergic conjunctivitis and dry eye syndrome.
@en
type
label
Emerging therapies in allergic conjunctivitis and dry eye syndrome.
@en
prefLabel
Emerging therapies in allergic conjunctivitis and dry eye syndrome.
@en
P2093
P2860
P1476
Emerging therapies in allergic conjunctivitis and dry eye syndrome.
@en
P2093
Leonard Bielory
Michael Nye
Shara Rudner
P2860
P304
P356
10.1517/14656566.2013.802773
P407
P577
2013-07-03T00:00:00Z